ARTICLE | Company News
Ablynx, Eddingpharm deal
September 8, 2014 7:00 AM UTC
Ablynx granted Eddingpharm exclusive rights in China, including Hong Kong and Macao, and Taiwan to develop and commercialize ozoralizumab ( ATN-103) for all indications. Ablynx will receive €2 million...